EP3079680A4 - Zusammensetzungen und verfahren zur behandlung, prävention und diagnose von krebs und anderen proliferativen erkrankungen - Google Patents

Zusammensetzungen und verfahren zur behandlung, prävention und diagnose von krebs und anderen proliferativen erkrankungen Download PDF

Info

Publication number
EP3079680A4
EP3079680A4 EP14870415.8A EP14870415A EP3079680A4 EP 3079680 A4 EP3079680 A4 EP 3079680A4 EP 14870415 A EP14870415 A EP 14870415A EP 3079680 A4 EP3079680 A4 EP 3079680A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treating
preventing
methods
proliferative disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14870415.8A
Other languages
English (en)
French (fr)
Other versions
EP3079680A2 (de
Inventor
William A. Garland
Jaideep Chaudhary
Glen STOLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogenex Inc
Original Assignee
Angiogenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenex Inc filed Critical Angiogenex Inc
Publication of EP3079680A2 publication Critical patent/EP3079680A2/de
Publication of EP3079680A4 publication Critical patent/EP3079680A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP14870415.8A 2013-12-13 2014-12-14 Zusammensetzungen und verfahren zur behandlung, prävention und diagnose von krebs und anderen proliferativen erkrankungen Withdrawn EP3079680A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361916116P 2013-12-13 2013-12-13
US201461965776P 2014-02-06 2014-02-06
PCT/US2014/070221 WO2015089495A2 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Publications (2)

Publication Number Publication Date
EP3079680A2 EP3079680A2 (de) 2016-10-19
EP3079680A4 true EP3079680A4 (de) 2017-11-22

Family

ID=53371974

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14870415.8A Withdrawn EP3079680A4 (de) 2013-12-13 2014-12-14 Zusammensetzungen und verfahren zur behandlung, prävention und diagnose von krebs und anderen proliferativen erkrankungen

Country Status (6)

Country Link
EP (1) EP3079680A4 (de)
JP (2) JP2017506257A (de)
CN (1) CN107847470A (de)
AU (1) AU2014361814A1 (de)
MX (1) MX2016007748A (de)
WO (1) WO2015089495A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
EP3416661A4 (de) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. Kombinationsimmuntherapie und cytokin-kontrolltherapie zur behandlung von krebs
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
EP3760614B8 (de) * 2019-07-02 2022-04-27 Universität Heidelberg Chemische inhibitoren von id-proteinen zur behandlung von krebs und anderen erkrankungen
JP2022550589A (ja) * 2019-10-01 2022-12-02 メモリアル スローン ケタリング キャンサー センター Ｉｄタンパク質の小分子阻害剤
CN113627763B (zh) * 2021-07-30 2023-12-01 厦门大学 一种风险量化评估模型建立方法
CN114480490A (zh) * 2021-12-31 2022-05-13 四川省医学科学院·四川省人民医院 一种构建视网膜新生血管性疾病动物模型的方法
CN115487358B (zh) * 2022-08-05 2023-05-30 核工业四一六医院 一种用于软骨组织修复的凝胶复合支架及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226422A1 (en) * 2007-10-16 2009-09-10 Jaideep Chaudhary Chemical Inhibitors of Inhibitors of Differentiation
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000036A1 (en) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226422A1 (en) * 2007-10-16 2009-09-10 Jaideep Chaudhary Chemical Inhibitors of Inhibitors of Differentiation
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAIDEEP CHAUDHARY ET AL: "A novel small molecule inhibitor of Id proteins (AGX-51) blocks cell survival in vitro and diminishes angiogenesis and tumor growth in vivo", THE FASEB JOURNAL, SUPPLEMENT, vol. 23, no. 1, 1 April 2009 (2009-04-01), pages 761.4, XP055388618 *
TIMMY MANI ET AL: "Probing Binding and Cellular Activity of Pyrrolidinone and Piperidinone Small Molecules Targeting the Urokinase Receptor", CHEMMEDCHEM, vol. 8, no. 12, 2 December 2013 (2013-12-02), DE, pages 1963 - 1977, XP055386919, ISSN: 1860-7179, DOI: 10.1002/cmdc.201300340 *

Also Published As

Publication number Publication date
WO2015089495A2 (en) 2015-06-18
WO2015089495A3 (en) 2015-11-12
EP3079680A2 (de) 2016-10-19
JP2019203028A (ja) 2019-11-28
AU2014361814A1 (en) 2016-07-28
MX2016007748A (es) 2017-07-28
JP2017506257A (ja) 2017-03-02
CN107847470A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
EP3060207A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
ZA201600453B (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
EP3041470A4 (de) Verfahren und zusammensetzungen zur selektiven und gezielten krebstherapie
EP3027192A4 (de) Verfahren zur behandlung fester tumore
PT2986304T (pt) Composição farmacêutica, métodos para o tratamento e suas utilizações
EP3079680A4 (de) Zusammensetzungen und verfahren zur behandlung, prävention und diagnose von krebs und anderen proliferativen erkrankungen
EP3166640A4 (de) Kombinationstherapiezusammensetzung und verfahren zur behandlung von krebs
EP3019243A4 (de) Verfahren zur behandlung oder prävention von augenerkrankungen
EP3076977A4 (de) Kombinationstherapie zur behandlung von krebs
IL241191B (en) Local compositions and kits that include them for the treatment of local disorders
EP3083569A4 (de) Benzodiazepinderivate, zusammensetzungen und verfahren zur behandlung von kognitiven störungen
EP3200815A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3077049A4 (de) Zusammensetzungen und verfahren zur behandlung von vitiligo
EP3085380A4 (de) Zusammensetzung zur behandlung von prostatakrebs
EP3033081A4 (de) Zusammensetzungen und verfahren zur behandlung von chronischer nesselsucht
EP3008167A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
EP2996721A4 (de) Verfahren und zusammensetzungen zur prognose, diagnose und behandlung von adam8-exprimierendem krebs
EP3004396A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP2989123A4 (de) Verfahren und zusammensetzungen zur behandlung von blutungsstörungen
AU2014306716B2 (en) Compositions and methods for treating celiac sprue disease
EP3052102A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3004395A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3066472A4 (de) Zusammensetzungen und verfahren zur erkennung und/oder behandlung von entzündungen
EP3065829A4 (de) Zusammensetzungen und verfahren zur behandlung von melanomen
EP3065550A4 (de) Verfahren und zusammensetzungen zur sepsis-behandlung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160707

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/04 20060101ALI20170714BHEP

Ipc: A61K 31/36 20060101ALI20170714BHEP

Ipc: A61K 45/06 20060101ALI20170714BHEP

Ipc: A61K 31/137 20060101AFI20170714BHEP

Ipc: A61P 35/00 20060101ALI20170714BHEP

Ipc: A61P 27/02 20060101ALI20170714BHEP

Ipc: A61P 43/00 20060101ALI20170714BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20171024

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20171018BHEP

Ipc: A61P 27/02 20060101ALI20171018BHEP

Ipc: A61K 31/137 20060101AFI20171018BHEP

Ipc: A61P 43/00 20060101ALI20171018BHEP

Ipc: A61P 35/04 20060101ALI20171018BHEP

Ipc: A61P 35/00 20060101ALI20171018BHEP

Ipc: A61K 31/36 20060101ALI20171018BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200728